Mode
Text Size
Log in / Sign up

Transcutaneous auricular vagus nerve stimulation improves dyspeptic symptoms and gastric accommodation in functional dyspepsiaVagus Nerve Stimulation Shows Promise for Functional Dyspepsia Symptoms

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that taVNS is a well-tolerated, non-invasive neuromodulation for improving dyspeptic symptoms and gastric accommodation.

This scoping review evaluates the efficacy and mechanism of transcutaneous auricular vagus nerve stimulation (taVNS) for the management of functional dyspepsia. The review synthesizes evidence from 480 clinical cases and 8 rodent studies to assess outcomes including dyspeptic symptoms, gastric accommodation, slow-wave normalization, and comorbid conditions such as anxiety, depression, and sleep disturbance.

The authors conclude that taVNS leads to significant improvements in dyspeptic symptoms and gastric accommodation. Furthermore, the intervention was associated with significant improvements in slow-wave normalization and comorbid anxiety, depression, and sleep disturbance. The review characterizes taVNS as a well-tolerated and mechanistically plausible non-invasive neuromodulation for functional dyspepsia acting on multiple brain-gut axis nodes.

Several limitations are noted, including a small number of trials, significant parameter heterogeneity, and limited follow-up periods. While the evidence suggests taVNS is a viable intervention, the low-to-moderate risk of bias in RCTs and the limited data mean that specific optimal regimens are not yet established. Clinical application should be viewed as a promising non-invasive option, though evidence is currently limited by the scope of available trials.

How this fits prior evidence

This scoping review addresses a gap in non-pharmacological management for functional dyspepsia. It complements existing evidence regarding the management of functional dyspepsia, such as the use of itopride as a convenient pharmacological option and the identification of metabolic and brain connectivity alterations as associated factors in the condition.

Researchers looked at how transcutaneous auricular vagus nerve stimulation (taVNS) affects people with functional dyspepsia. This condition involves chronic stomach discomfort without an obvious physical cause. The review looked at 480 clinical cases and 8 animal studies to see how this non-invasive nerve stimulation works.

The findings suggest that taVNS may improve several symptoms. These include better stomach accommodation, fewer dyspeptic symptoms, and improved sleep. The study also noted improvements in related issues like anxiety and depression. The treatment was reported to be well-tolerated by those who received it.

Because this was a scoping review of a small number of trials, the results are not yet definitive. There is a lot of variation in how the treatment was applied in different studies. While the results are promising, more large-scale research is needed to establish the best way to use this treatment for patients.

What this means for you:
Vagus nerve stimulation may help manage stomach discomfort and related issues, but more research is needed.

Common questions

What is functional dyspepsia?

Functional dyspepsy is a condition where people experience chronic stomach discomfort and other digestive issues. It is often linked to the brain-gut axis. This study looked at how a non-invasive nerve stimulation called taVNS might help manage these symptoms and related issues like sleep problems.

Is the nerve stimulation treatment safe?

The treatment, known as taVNS, was reported to be well-tolerated by participants in the studies reviewed. No serious adverse events were reported in the data. However, because the evidence comes from a small number of trials, you should talk to your doctor about the best options for your specific health needs.

What specific symptoms can this treatment help with?

The review found that taVNS may lead to significant improvements in dyspeptic symptoms and gastric accommodation. It also showed potential benefits for related conditions, including anxiety, depression, and sleep disturbances. These findings are based on a mix of human and animal studies.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
BackgroundFunctional dyspepsia (FD) is a common gut–brain interaction disorder with suboptimal response to pharmacotherapy. Transcutaneous auricular vagus nerve stimulation (taVNS), a non-invasive neuromodulation targeting the vagus nerve, has emerged as a promising brain–gut axis therapy. This scoping review (PRISMA-ScR, JBI methodology) synthesizes clinical and preclinical mechanistic evidence on taVNS for FD.MethodsPubMed, Embase, Web of Science, and Cochrane Library were searched up to December 20, 2025, following PRISMA-ScR. Using PICOS (adults with FD; taVNS; sham/non-vagal/active controls; symptoms, gastric function, psychological outcomes, biomarkers; RCTs/clinical trials and controlled animal studies), two reviewers independently screened, extracted data, and assessed bias (RoB2 for RCTs, SYRCLE for animal studies). A narrative synthesis was performed due to heterogeneity.ResultsFour RCTs (n = 480) and eight preclinical rodent studies met inclusion. All RCTs showed significant improvements in dyspeptic symptoms, gastric accommodation, slow-wave normalization, and comorbid anxiety, depression, sleep disturbance versus sham/non-vagal control, sustained for 4–12 weeks. Stimulation parameters varied (10–30 Hz; 0.5–10 mA; 2–4 weeks); risk of bias low-moderate. Preclinical rodent evidence supported five interconnected candidate mechanisms: (i) autonomic balance and cholinergic modulation; (ii) α7nAChR/NF-κB anti-inflammatory pathway with duodenal barrier restoration; (iii) NGF/TrkA/PLC-γ/TRPV1-mediated visceral hypersensitivity suppression; (iv) HPA axis inhibition; (v) rebalancing of brain-gut peptides (motilin, CCK, GLP-1).ConclusionThis review characterizes taVNS as a safe, well-tolerated, mechanistically plausible non-invasive neuromodulation for FD acting on multiple brain–gut axis nodes. However, the small number of trials, parameter heterogeneity, and limited follow-up constrain definitive conclusions. Adequately powered, multicenter RCTs with standardized protocols and long-term follow-up are needed to confirm efficacy and define optimal regimens.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.